Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
The AAV9 gene therapy vector presented in this study is safe in mice and non-human primates and highly efficacious without causing overexpression toxicity, a major challenge for clinical translation of Rett syndrome gene therapy vectors to date. Our team designed a new truncated methyl-CpG-binding protein 2 (MECP2) promoter allowing widespread expression of MECP2 in mice and non-human primates after a single injection into the cerebrospinal fluid without causing overexpression symptoms up to 18 months after injection. Additionally, this new vector is highly efficacious at lower doses compared with previous constructs as demonstrated in extensive efficacy studies performed by two independent laboratories in two different Rett syndrome mouse models carrying either a knockout or one of the most frequent human mutations of Mecp2. Overall, data from this multicenter study highlight the efficacy and safety of this gene therapy construct, making it a promising candidate for first-in-human studies to treat Rett syndrome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Molecular therapy : the journal of the American Society of Gene Therapy - 31(2023), 9 vom: 06. Sept., Seite 2767-2782 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Powers, Samantha [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adeno-associated virus serotype 9, scAAV9 |
|---|
| Anmerkungen: |
Date Completed 11.09.2023 Date Revised 17.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ymthe.2023.07.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359819516 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359819516 | ||
| 003 | DE-627 | ||
| 005 | 20231226081706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ymthe.2023.07.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1199.xml |
| 035 | |a (DE-627)NLM359819516 | ||
| 035 | |a (NLM)37481701 | ||
| 035 | |a (PII)S1525-0016(23)00393-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Powers, Samantha |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Novel MECP2 gene therapy is effective in a multicenter study using two mouse models of Rett syndrome and is safe in non-human primates |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.09.2023 | ||
| 500 | |a Date Revised 17.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a The AAV9 gene therapy vector presented in this study is safe in mice and non-human primates and highly efficacious without causing overexpression toxicity, a major challenge for clinical translation of Rett syndrome gene therapy vectors to date. Our team designed a new truncated methyl-CpG-binding protein 2 (MECP2) promoter allowing widespread expression of MECP2 in mice and non-human primates after a single injection into the cerebrospinal fluid without causing overexpression symptoms up to 18 months after injection. Additionally, this new vector is highly efficacious at lower doses compared with previous constructs as demonstrated in extensive efficacy studies performed by two independent laboratories in two different Rett syndrome mouse models carrying either a knockout or one of the most frequent human mutations of Mecp2. Overall, data from this multicenter study highlight the efficacy and safety of this gene therapy construct, making it a promising candidate for first-in-human studies to treat Rett syndrome | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a P546 | |
| 650 | 4 | |a Rett syndrome | |
| 650 | 4 | |a adeno-associated virus serotype 9, scAAV9 | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a methyl-CpG binding protein 2, MECP2 | |
| 700 | 1 | |a Likhite, Shibi |e verfasserin |4 aut | |
| 700 | 1 | |a Gadalla, Kamal K |e verfasserin |4 aut | |
| 700 | 1 | |a Miranda, Carlos J |e verfasserin |4 aut | |
| 700 | 1 | |a Huffenberger, Amy J |e verfasserin |4 aut | |
| 700 | 1 | |a Dennys, Cassandra |e verfasserin |4 aut | |
| 700 | 1 | |a Foust, Kevin D |e verfasserin |4 aut | |
| 700 | 1 | |a Morales, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a Pierson, Christopher R |e verfasserin |4 aut | |
| 700 | 1 | |a Rinaldi, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Perry, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Bolon, Brad |e verfasserin |4 aut | |
| 700 | 1 | |a Wein, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Cobb, Stuart |e verfasserin |4 aut | |
| 700 | 1 | |a Kaspar, Brian K |e verfasserin |4 aut | |
| 700 | 1 | |a Meyer, Kathrin C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular therapy : the journal of the American Society of Gene Therapy |d 2000 |g 31(2023), 9 vom: 06. Sept., Seite 2767-2782 |w (DE-627)NLM108239381 |x 1525-0024 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2023 |g number:9 |g day:06 |g month:09 |g pages:2767-2782 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ymthe.2023.07.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2023 |e 9 |b 06 |c 09 |h 2767-2782 | ||